Already sky-high expectations for the experimental cancer drug ibrutinib from J&J and Pharmacyclics managed to arc even higher this morning after the collaborators spread word that the program had just won its third "breakthrough drug" title from the FDA.
Johnson & Johnson scored a major victory with the FDA this month when the agency put its breakthrough designation on an investigational cancer drug, and now Abbott Laboratories is stepping in to develop a companion diagnostic for the headline-grabbing compound.
J&J and Pharmacyclics nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year.
Pharmacyclics' closely watched leukemia drug ibrutinib has been attracting some strong buzz recently.
Partnered with J&J in a major market deal, Pharmacyclics demonstrated fresh evidence that ibrutinib could control malignancies in patients who were both treatment naïve and unresponsive to other meds.
J&J stepped in with a blockbuster licensing deal for Pharmacyclics' late-stage blood cancer drug ibrutinib late last year, and ever since it's been keeping up a rich flow of milestone payments promised in the $975 million deal.